{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:17:42Z","timestamp":1789777062928,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.antiviral.2019.104537","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:11:07Z","timestamp":1560510667000},"page":"104537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems."],"prefix":"10.1016","volume":"169","author":[{"given":"Yasunori","family":"Nio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Akahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Ryo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hijikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104537_bib1","doi-asserted-by":"crossref","first-page":"15958","DOI":"10.1074\/jbc.M116.724641","article-title":"RNA exosome complex regulates stability of the hepatitis B virus X-mRNA transcript in a non-stop-mediated (NSD) RNA quality control mechanism","volume":"291","author":"Aly","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.104537_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.104537_bib3","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1128\/AAC.02053-12","article-title":"Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction","volume":"57","author":"Chen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104537_bib4","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2019.104537_bib5","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2019.104537_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000489998","article-title":"Bardoxolone methyl suppresses hepatitis B virus large surface protein variant W4P-related carcinogenesis and hepatocellular carcinoma cell proliferation via the inhibition of signal transducer and activator of transcription 3 signaling","volume":"102","author":"Gee","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.antiviral.2019.104537_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104537_bib8","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-11-2703","article-title":"A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas","volume":"18","author":"Hong","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2019.104537_bib9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ajpath.2015.01.028","article-title":"Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice","volume":"185","author":"Ishida","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.antiviral.2019.104537_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"Iwamoto","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2019.104537_bib11","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.1128\/JVI.00402-10","article-title":"A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production","volume":"84","author":"Kushima","year":"2010","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2019.104537_bib12","first-page":"61","article-title":"Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants","volume":"25","author":"Lam","year":"2017","journal-title":"Antimicrob. Agents Chemother. Jul."},{"key":"10.1016\/j.antiviral.2019.104537_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"Levrero","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.104537_bib14","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/JVI.02147-07","article-title":"Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104537_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ncb1631","article-title":"The lipid droplet is an important organelle for hepatitis C virus production","volume":"9","author":"Miyanari","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.antiviral.2019.104537_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.antiviral.2016.07.003","article-title":"Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment","volume":"132","author":"Nio","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104537_bib17","doi-asserted-by":"crossref","DOI":"10.5812\/ijhrba.25028","article-title":"Prevalence of HCV infections and co-infection with HBV and HIV and associated risk factors among addicts in drug treatment centers, Lorestan Province, Iran","volume":"5","author":"Norouzian","year":"2016","journal-title":"Int. J. High Risk Behav. Addict."},{"key":"10.1016\/j.antiviral.2019.104537_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2014.08.029","article-title":"Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line","volume":"452","author":"Ogura","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2019.104537_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbrc.2016.05.043","article-title":"Fatty acid biosynthesis is involved in the production of hepatitis B virus particles","volume":"475","author":"Okamura","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2019.104537_bib20","doi-asserted-by":"crossref","first-page":"17047","DOI":"10.1038\/srep17047","article-title":"Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide","volume":"5","author":"Okuyama-Dobashi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.104537_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104537_bib22","first-page":"536","article-title":"Black box warning for possible HBV reactivation during DAA therapy for chronic HCV infection","volume":"13","author":"Pockros","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104537_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2007.07.021","article-title":"Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection","volume":"133","author":"Protzer","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104537_bib24","doi-asserted-by":"crossref","first-page":"45698","DOI":"10.1038\/srep45698","article-title":"Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection","volume":"7","author":"Sakurai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.104537_bib26","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.104537_bib27","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus -15 years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.104537_bib28","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.antiviral.2019.104537_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.21345","article-title":"Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens","volume":"44","author":"Sugiyama","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104537_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089869","article-title":"Critical role of interferon-\u03b1 constitutively produced in human hepatocytes in response to RNA virus infection","volume":"9","author":"Tsugawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104537_bib32","doi-asserted-by":"crossref","first-page":"31715","DOI":"10.1074\/jbc.M113.501122","article-title":"Interleukin-1 and tumor necrosis factor-\u03b1 trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)","volume":"288","author":"Watashi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.104537_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2019.104537_bib34","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jgh.13771","article-title":"Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals","volume":"32","author":"Yeh","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104537_bib35","article-title":"Sulforaphane suppresses hepatitis C virus replication by up-regulating heme oxygenase-1 expression through PI3K\/Nrf2 pathway","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:48Z","timestamp":1759062528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":33,"alternative-id":["S0166354218305345"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104537","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104537"}}